Netherlands· NL-dc6f183ce75f

Bezalip Retard 400 mg, tabletten met gereguleerde afgifte

A bezafibrate product containing bezafibraat, registered in Netherlands by EU-Pharma B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC C10AB02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about bezafibraatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Bezafibrate is registered in 10 of 19 countries.

Countries holding a registration under ATC C10AB02 (bezafibrate), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
6 of them publish a price we can compare per daily dose

Search bezafibrate products by name

Bezafibrate · ATC C10AB02

10 / 19 countries

Belgiumprice
Canada
Finlandprice
Franceprice
Germany
Italyprice
Netherlands
Norwayprice
Switzerlandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bezafibrate costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.29 in France to $1.19 in Switzerland — a ×4.1 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Bezafibrate · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

CH Switzerland$1.19
IT Italy$0.44
FR France$0.29

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: BEZAFIBRAAT
Manufacturer: EU-Pharma B.V.
Country: Netherlands (NL)
ATC code: C10AB02
ATC class: Bezafibrate
Defined daily dose: 0.6 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
132379//18388

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Bezafibrate in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bezafibrate products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

Austria · Bezalip Retard, Bezastad
Belgium · Cedur, Eulitop
Cyprus · Lacromid, Zafibral
Germany · Bezafibrat Al, Bezafibrat Retard Al
Spain · Eulitop, Eulitop Retard
Finland · Bezalip
France · Befizal, Befizal L.P.
United Kingdom (Northern Ireland) · Bezafibrate, Bezafibrate Noumed Life Sciences
Hungary · Bezalip
Italy · Bezalip
Luxembourg · Cedur, Eulitop
Portugal · Bezalip, Bezalip Retard
Romania · Bezafibrat Arena
Sweden · Bezalip, Bezalip Retard

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/46225650-3fce-4c3a-80e9-bba1db95f94d
GET /v1/drugs/46225650-3fce-4c3a-80e9-bba1db95f94d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet met verlengde afgifte",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h18388_smpc.pdf",
  "strength": null,
  "atc_label": "Bezafibrate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg132379",
  "excipients": [
    "COPOLYMEER VAN ETHYLACRYLAAT-METHYLMETHACRYLAAT (2:1) (E 1206)",
    "HYPROMELLOSE (Release controlling polymer)(E 464)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 10000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "POLYSORBAAT 80 (E 433)",
    "POVIDON K 25 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)"
  ],
  "substances": [
    "BEZAFIBRAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h132379.pdf",
  "authorised_at": "2024/08/28",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "132379//18388",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about bezafibrate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console